US protection ending in 2026: Skin and connective tissue
As of the edition of 20 October 2026, 16 drugs have US protection that ends (or has ended) in 2026 in skin and connective tissue; 8 of them have at least one company on route B because of it.
Sources: FDA Orange Book and Purple Book, other approval registers.
16 drugs
| Drug | US protection | Status | Holder | Target | Route B rows |
|---|---|---|---|---|---|
| Afamelanotide | Ended 2026 (exclusivity) | Marketed | Clinuvel | MC1R | 1 |
| Belinostat | Ended 2026 (patent) | Marketed | Acrotech Biopharma | 0 | |
| Conestat alfa | Ended 2026 (reference-product exclusivity) | Marketed | Pharming Americas BV | 0 | |
| Dasatinib anhydrous | Ended 2026 (exclusivity) | Marketed | ABL1, BLK, FGR | 12 | |
| Elosulfase alfa | Ended 2026 (computed from the first US licence) | Marketed | Amicus Therapeutics | 0 | |
| Eribulin | Ended 2026 (exclusivity) | Marketed | Eisai | TUBB, TUBB1, TUBB2A | 9 |
| Escitalopram | Ended 2026 (exclusivity) | Marketed | AbbVie | SLC6A4 | 4 |
| Lacosamide | Ended 2026 (exclusivity) | Marketed | UCB | SCN10A, SCN11A, SCN1A | 0 |
| Leuprolide | Ended 2026 (exclusivity) | Marketed | GNRHR | 1 | |
| Metreleptin | Ended 2026 (computed from the first US licence) | Marketed | Chiesi Farmaceutici | LEPR | 0 |
| Onabotulinumtoxina | Ended 2026 (orphan exclusivity) | Marketed | AbbVie | SNAP25 | 0 |
| Pasireotide | Ends 2026 (patent) | Marketed | Recordati Rare Diseases | SSTR2, SSTR3, SSTR5 | 0 |
| Peginterferon beta-1a | Ended 2026 (computed from the first US licence) | Marketed | Biogen | IFNAR1, IFNAR2 | 0 |
| Ramucirumab | Ended 2026 (orphan exclusivity) | Marketed | Eli Lilly | KDR | 1 |
| Sitagliptin | Ends 2026 (patent) | Marketed | Merck & Co. | DPP4 | 1 |
| Vedolizumab | Ended 2026 (computed from the first US licence) | Marketed | Takeda | ITGA4 | 1 |
Listed by name. A route B row is one company at one target; for a drug with one target that is the number of companies. US protection is the US only, and it is not the date generics or biosimilars can enter.
Which companies are on route B in 2026 in skin and connective tissue
In the product8 of these 16 drugs have at least one company on route B. Which companies, and their scores, are in the product.
Get this list with the companies, scores and sources as a fileRequest access. Nothing is shown until you do.